Finance entity
markets is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention Vertex Pharmaceuticals, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 177-day span.
Last mentioned: 18h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention Vertex Pharmaceuticals, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 177-day span. Their average consequence score of 5 runs below the beat's 6.2 for that window. Source depth averages 2 original sources per story, versus 2.7 across the same-window beat baseline. This profile follows 2 Finance stories mentioning CRISPR Therapeutics across the period from March 11, 2026 to September 3, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 3047 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CRISPR Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Offering Upsized
The company prices an upsized $550M offering due to strong institutional interest.
ARK Invest Trade
Cathie Wood's ARK Invest buys the dip, increasing its position in CRSP shares.
Debt Offering Announced
CRISPR Therapeutics announces a $350M convertible senior notes offering, causing a stock price dip.
CRISPR Therapeutics has lagged the broader market in 2026, but Casgevy's label expansion and upcoming clinical readouts create two discrete catalysts that could re-rate the stock. Downside risk remains from slow uptake and high cost.
ARK Invest founder Cathie Wood has increased her stake in CRISPR Therapeutics following a stock price decline triggered by a significant convertible debt offering. The move underscores Wood's long-term conviction in the gene-editing sector despite short-term market volatility and capital-raising pressures.
CRISPR Therapeutics is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
